HOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITIS
MEETS PRIMARY AND SECONDARY ENDPOINTS SAFETY AND EFFICACYBIOLEXA led to significant improvement in disease severity as measured by SCORAD and EASI...
Source: businessinsider.com